Amylin analog · AM833
Cagrilintide
Trial Often paired with semaglutide in CagriSema
What it is
Cagrilintide is a long-acting amylin analogue developed for obesity, including the CagriSema combination with semaglutide. Research vials with this name are not trial drug.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- A long-acting amylin look-alike. Amylin is the hormone that says “you’ve eaten enough” alongside insulin.
- In trials (often with semaglutide as CagriSema) it adds more fullness and weight change.
- Nausea and stomach slowing are the expected costs, same family as other satiety shots.
- Not a research-vial substitute for a trial product.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Amylin-receptor activity slows gastric emptying, reduces food intake, and complements GLP-1. That is why combination programs exist.
Possible side effects / caveats
Nausea and other GI events, as with incretin/amylin drugs. Titration is part of the trial design for a reason.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Trial talk | About 0.3–4.5 mg weekly | Once weekly, titrated | Order-of-magnitude from development programs |